Enantiomerically pure .beta.-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5444063A · kind A · utility
53Cited by
13References
12Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 28, 1992 |
| Grant date | Aug 22, 1995 |
| Priority date | — |
| Expiry date | Oct 28, 2012 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D497/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method and composition for the treatment of humans infected with HBV that includes the administration of an HBV treatment amount of a .beta.-dioxolanyl purine nucleoside of the formula: ##STR1## wherein R is OH, Cl, NH.sub.2, or H, or a pharmaceutically acceptable salt or derivative of the compound, optionally in a pharmaceutically acceptable carrier or diluent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.